Biotechnology company Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) fell about 10% in trading on Wednesday, May 20 following the company’s announcement that it licensed its …
Cowen analyst Phil Nadeau weighed in today with a few observations on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), following the company’s announcement that it has partnered its …
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced today that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Gilead Sciences, Inc.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Achillion Pharmaceuticals stock is soaring in the market today.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the …
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) jumped almost 20% in trading on February 9th after the company announced positive interim data results for its hepatitis …
In a research report issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on Achillion Pharmaceuticals (NASDAQ:ACHN) with a $22 price target, as …
Cowen’s healthcare analyst Phil Nadeau is weighing in with a few insights on Achillion Pharmaceuticals (NASDAQ:ACHN), following new trial results which demonstrated that a combination of the …
2014 was an eventful year on Wall Street with many ups and downs. Although many analyst recommendations made in 2014 were profitable, many …
